Literature DB >> 1645379

Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin).

H Swars1, G Hafner, L S Weilemann, W Ehrenthal, H Schinzel, W Prellwitz, J Meyer.   

Abstract

Despite the improvements in the development of dialyzer membranes with greater hemocompatibility, an activation of the coagulation system occurs when blood comes into contact with exogenous surfaces. The large number of heparin dosage regimens demonstrated the difficulty to adapt general therapeutic guidelines. Low molecular weight heparin (Fragmin) was administered as a single bolus dose for anticoagulation during 58 acute dialyses. Anti-Xa-activity, the plasma levels of the lysosomal elastase of the polymorphonuclear granulocytes ("PMN-elastase") and of the thrombin-antithrombin III-complex (TAT) were measured at hourly intervals. Therapeutic anti-Xa-levels did not show evidence of sufficient inhibition of thrombin formation. The PMN-elastase increased by 180 ng/ml 3 h after administration of the bolus dose, with no further increase occurring (plateau phase). This was considered to reflect adequate anticoagulative activity. Where anticoagulation was inadequate, the elastase values rose consistently. After 2 h the increase of the PMN-elastase showed that--and to what extent--coagulation had been activated. The determination of PMN-elastase, using the IMAC-principle, is a method which can be performed quickly with any conventional autoanalyzer. It makes it possible to monitor adequate anticoagulation, but PMN-elastase results must be proven during routine use before recommendation as a routine test.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645379     DOI: 10.1007/bf01708410

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  16 in total

1.  Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay.

Authors:  H Pelzer; A Schwarz; N Heimburger
Journal:  Thromb Haemost       Date:  1988-02-25       Impact factor: 5.249

2.  A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.

Authors:  B Ljungberg; M Blombäck; H Johnsson; L E Lins
Journal:  Clin Nephrol       Date:  1987-01       Impact factor: 0.975

3.  Surface activation of blood coagulation, fibrinolysis and kinin formation.

Authors:  R L Heimark; K Kurachi; K Fujikawa; E W Davie
Journal:  Nature       Date:  1980-07-31       Impact factor: 49.962

Review 4.  Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy.

Authors:  D I Feinstein
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

5.  Evidence for the formation of an ester between thrombin and heparin cofactor.

Authors:  W G Owen
Journal:  Biochim Biophys Acta       Date:  1975-10-20

6.  Low molecular weight (LMW) heparin derivatives in experimental extra-corporeal circulation (ECC).

Authors:  M Aiach; G Dreyfus; A Michaud; J Relland; M Murawski; M Leclerc; A Carpentier
Journal:  Haemostasis       Date:  1984

7.  Plasma levels of granulocyte elastase during hemodialysis: effects of different dialyzer membranes.

Authors:  W H Hörl; H B Steinhauer; P Schollmeyer
Journal:  Kidney Int       Date:  1985-11       Impact factor: 10.612

8.  Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications.

Authors:  C P Henny; H Ten Cate; J W Ten Cate; S Surachno; H van Bronswijk; J M Wilmink; P A Ockelford
Journal:  Lancet       Date:  1983-04-23       Impact factor: 79.321

9.  Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.

Authors:  D A Lane; H Ireland; A Flynn; E Anastassiades; J R Curtis
Journal:  Nephrol Dial Transplant       Date:  1986       Impact factor: 5.992

10.  Low molecular weight heparin in hemodialysis and hemofiltration patients.

Authors:  J Schrader; R Valentin; H J Tönnis; U Hildebrand; W Stibbe; V W Armstrong; M Kandt; H Köstering; E Quellhorst
Journal:  Kidney Int       Date:  1985-11       Impact factor: 10.612

View more
  2 in total

Review 1.  What are the anticoagulation options for intermittent hemodialysis?

Authors:  Andrew Davenport
Journal:  Nat Rev Nephrol       Date:  2011-07-05       Impact factor: 28.314

2.  The effects of citrate dialysate in hemodialysis on polymorphonuclear elastase interaction with tissue factor and its inhibitor.

Authors:  Jiameng Li; Si Sun; Mei Han; Liya Wang; Ruoxi Liao; Yuqin Xiong; Yupei Li; Heng Jiang; Zheng Qin; Anil Maharjan; Mario Cozzolino; Alexander Zarbock; Baihai Su
Journal:  Ann Transl Med       Date:  2019-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.